ASH Presentation Shows Continued Treatment With Azacitidine Improves Responses In Patients With Higher-Risk Myelodysplastic Syndromes

Celgene UK today reports that an analysis presented today of a phase III international clinical trial (AZA-001) of higher-risk patients with myelodysplastic syndromes (MDS), demonstrated that continued treatment with azacitidine can improve patient responses. The data were presented at the 50th Annual American Society of Hematology meeting in San Francisco, CA.

More: continued here

Filed under: Blood on December 11th, 2008